Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

37.19USD
18 Dec 2017
Change (% chg)

$-0.00 (-0.01%)
Prev Close
$37.20
Open
$37.22
Day's High
$37.35
Day's Low
$37.06
Volume
9,253,423
Avg. Vol
16,249,032
52-wk High
$37.35
52-wk Low
$30.90

Latest Key Developments (Source: Significant Developments)

Pfizer Authorizes New $10 Billion Share Repurchase Program, Ups Dividend
11:44am EST 

Dec 18 (Reuters) - Pfizer ::PFIZER INC - BOARD OF DIRECTORS APPROVES INCREASE IN QUARTERLY CASH DIVIDEND TO $0.34 PER SHARE AND AUTHORIZES NEW $10 BILLION SHARE REPURCHASE PROGRAM.PFIZER INC - INCREASES QUARTERLY DIVIDEND BY 6 PERCENT TO $0.34 PER SHARE.PFIZER INC - NEW BUYBACK PROGRAM IS IN ADDITION TO $6.4 BILLION REMAINING UNDER COMPANY'S CURRENT AUTHORIZATION.  Full Article

Pfizer Announces FDA Approval Of Xeljanz® And Xeljanz® Xr For Treatment Of Active Psoriatic Arthritis
Thursday, 14 Dec 2017 07:26pm EST 

Dec 14 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES FDA APPROVAL OF XELJANZ® (TOFACITINIB) AND XELJANZ® XR FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS.SAYS ‍BOTH PIVOTAL STUDIES MET THEIR TWO PRIMARY EFFICACY ENDPOINTS​.‍SAFETY PROFILE OBSERVED IN PATIENTS TREATED WITH XELJANZ CONSISTENT WITH SAFETY PROFILE OBSERVED IN RHEUMATOID ARTHRITIS PATIENTS​.  Full Article

Pfizer Announces Pricing Terms Of Private Exchange Offer For 6.500 PCT Notes Due 2038
Thursday, 14 Dec 2017 10:27am EST 

Dec 14 (Reuters) - Pfizer Inc ::PFIZER INC ANNOUNCES PRICING TERMS OF PRIVATE EXCHANGE OFFER FOR ITS 6.500 PER CENT. NOTES DUE 2038 OPEN TO CERTAIN INVESTORS AND RELATED TENDER OFFER OPEN TO ALL INVESTORS.SAYS ‍PRICING TERMS OF OFFERS TO EXCHANGE AND TO REPURCHASE ANY AND ALL OF ITS OUTSTANDING £1.5 BILLION 6.500 PERCENT NOTES DUE 2038​.  Full Article

Pfizer Initiates Phase 3 Program For Pf-04965842, A Jak1 Inhibitor In Development For Moderate-To-Severe Atopic Dermatitis
Thursday, 14 Dec 2017 07:30am EST 

Dec 14 (Reuters) - Pfizer Inc ::PFIZER INITIATES PHASE 3 PROGRAM FOR PF-04965842, A JAK1 INHIBITOR IN DEVELOPMENT FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS.PFIZER INC - ‍GLOBAL PROGRAM TO COMMENCE WITH PIVOTAL STUDY B7451012 IN NORTH AMERICA, AUSTRALIA AND EUROPE; BROADER REGIONAL ROLLOUT IN 2018​.  Full Article

FDA Approves Pfizer's New Biosimilar To Remicade
Wednesday, 13 Dec 2017 06:01pm EST 

Dec 13 (Reuters) - Pfizer Inc ::FDA APPROVES NEW PFIZER BIOSIMILAR.PFIZER INC - UNITED STATES FOOD AND DRUG ADMINISTRATION HAS APPROVED IXIFI AS A BIOSIMILAR TO REMICADE.  Full Article

Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies
Wednesday, 13 Dec 2017 01:56am EST 

Dec 13 (Reuters) - CELLECTIS ::SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.STUDIES DEMONSTRATED SAFETY AND TOLERABILITY OF UCART19.STUDIES RESULTED IN 83-PCT COMPLETE REMISSION RATE ACROSS THE PATIENT POPULATION.IN 'CALM' TRIAL (UCART19 IN ADVANCED LYMPHOID MALIGNANCIES) FOR ADULTS, FIVE OUT OF SEVEN PATIENTS ACHIEVED MOLECULAR REMISSION AT DAY 28.'CALM' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED; CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.ONE PATIENT IN 'CALM' TRIAL DEVELOPED GRADE 4 CYTOKINE RELEASE SYNDROME AND NEUTROPENIC SEPSIS LEADING TO DEATH AT DAY 15.IN 'PALL' TRIAL (PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA) FOR CHILDREN, ALL FIVE PATIENTS ACHIEVED MOLECULAR REMISSION;.'PALL' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED.'PALL TRIAL': CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.  Full Article

U.S. FDA Extends Action Date For Expanded Label of Pfizer's Xeljanz In Ulcerative Colitis By Three Months
Tuesday, 12 Dec 2017 04:52pm EST 

Dec 12 (Reuters) - Pfizer Inc ::U.S. FOOD AND DRUG ADMINISTRATION EXTENDS ACTION DATE FOR XELJANZ® (TOFACITINIB) SUPPLEMENTAL NEW DRUG APPLICATION IN ULCERATIVE COLITIS BY THREE MONTHS.PFIZER INC - FDA HAS PROVIDED AN ANTICIPATED PRESCRIPTION DRUG USER FEE ACT DATE IN JUNE 2018.PFIZER INC - DRUG HAS BOXED WARNING REGARDING PATIENTS TREATED WITH XELJANZ/XELJANZ XR ARE AT INCREASED RISK FOR DEVELOPING SERIOUS INFECTIONS.  Full Article

Teva Announces Exclusive Launch Of Generic Viagra Tablets In The United States
Monday, 11 Dec 2017 09:13am EST 

Dec 11 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIAGRA® TABLETS IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍EXCLUSIVE LAUNCH OF ITS GENERIC VIAGRA TABLETS IN U.S​.  Full Article

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings
Monday, 11 Dec 2017 08:45am EST 

Dec 11 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS.PUMA BIOTECHNOLOGY - EUROPEAN PATENT OFFICE HAS UPHELD CLAIMS IN PUMA'S LICENSED EUROPEAN PATENT, EP 2416774, WHICH WERE BEING OPPOSED BY HEXAL AG.  Full Article

Pfizer Inc Announces Private Exchange Offer For Its 6.500 Per Cent Notes Due 2038
Thursday, 7 Dec 2017 08:00am EST 

Dec 7 (Reuters) - Pfizer Inc ::PFIZER INC. ANNOUNCES (I) PRIVATE EXCHANGE OFFER FOR ITS 6.500 PER CENT. NOTES DUE 2038 OPEN TO CERTAIN INVESTORS AND RELATED TENDER OFFER OPEN TO ALL INVESTORS AND (II) TENDER OFFER FOR ITS 5.750 PER CENT. NOTES DUE 2021 AND RELATED SOLICITATION OF CONSE.PFIZER INC - COMMENCED A PRIVATE OFFER TO EXCHANGE ANY AND ALL OF ITS OUTSTANDING GBP 1.5 BILLION 6.500 PER CENT.PFIZER INC- EXCHANGE OFFER WILL EXPIRE AT 5:00 P.M. (NEW YORK TIME) ON DECEMBER 14, 2017.  Full Article

Photo

Pfizer announces new $10 billion share buyback, hikes dividend

Pfizer Inc said on Monday its board had authorized a new $10 billion share repurchase program and raised its quarterly dividend.